SCOPUS 정보 검색 플랫폼

Journal of the American Academy of Dermatology

Volumn 59, Issue 1, 2008, Pages 165-167

Rethinking eligibility creep

(6) Kazanis, Maryanne a Leonardi, Craig b Gordon, Ken c Strober, Bruce d Menter, Alan e Kimball, Alexa B f

a BRIGHAM AND WOMEN S HOSPITAL (United States)

b Central Dermatology (United States)

c NORTHWESTERN UNIVERSITY (United States)

d NEW YORK UNIVERSITY MEDICAL CENTER (United States)

e Texas Dermatology Associates PA (United States)

f HARVARD MEDICAL SCHOOL (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB;

CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE SEVERITY; HUMAN; LETTER; MEDICAL LITERATURE; MONOTHERAPY; PRIORITY JOURNAL; PSORIASIS; SCORING SYSTEM;

ANTIBODIES, MONOCLONAL; CONTROLLED CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOGLOBULIN G; PATIENT SELECTION; PLACEBO EFFECT; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 45149134742 PISSN: 01909622 EISSN: None Source Type: Journal
DOI: 10.1016/j.jaad.2008.02.041 Document Type: Letter

Times cited : (1)

References (5)

1
- 36048963546
- Eligibility creep: A cause of placebo group improvement in controlled trials of psoriasis treatments
- Hick J., and Feldman S.R. Eligibility creep: A cause of placebo group improvement in controlled trials of psoriasis treatments. J Am Acad Dermatol 57 (2007) 972-976
- (2007) J Am Acad Dermatol , vol.57 , pp. 972-976
- Hick, J.¹ Feldman, S.R.²

2
- 4544240454
- Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased
- Jacobson C.C., and Kimball A.B. Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased. Br J Dermatol 151 (2004) 381-387
- (2004) Br J Dermatol , vol.151 , pp. 381-387
- Jacobson, C.C.¹ Kimball, A.B.²

3
- 2542445474
- A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis
- Carlin C.S., Feldman S.R., Krueger J.G., Menter A., and Krueger G.G. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 50 (2004) 859-866
- (2004) J Am Acad Dermatol , vol.50 , pp. 859-866
- Carlin, C.S.¹ Feldman, S.R.² Krueger, J.G.³ Menter, A.⁴ Krueger, G.G.⁵

4
- 45149134203
- Gottlieb A. How well do rheumatologists and dermatologists assess psoriasis and psoriatic arthritis? Results of an international, GRAPPA-sponsored, reliability study. Presented at the 21st Congress of World Dermatology, Buenos Aires, Argentina, September 30-October 10, 2007.
- Gottlieb A. How well do rheumatologists and dermatologists assess psoriasis and psoriatic arthritis? Results of an international, GRAPPA-sponsored, reliability study. Presented at the 21st Congress of World Dermatology, Buenos Aires, Argentina, September 30-October 10, 2007.

5
- 35348895188
- Psoriasis and psoriatic arthritis: separate or one and the same?
- Ciocon D., and Kimball A.B. Psoriasis and psoriatic arthritis: separate or one and the same?. Br J Dermatol 157 (2007) 850-860
- (2007) Br J Dermatol , vol.157 , pp. 850-860
- Ciocon, D.¹ Kimball, A.B.²

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.